NCT00473590: Phase 2 - Bevacizumab in Combination With Bortezomib in MM (AMBER)
Updated: Jun 15, 2022
NCT00473590: Phase 2: A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) (AMBER)
This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or refractory multiple myeloma.
Sponsor
Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00473590
Official Title: A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : May 15, 2007
Click here for details on ClinicalTrials.gov
Drug: Bevacizumab
Drug: Bortezomib
Drug: placebo
Cancer; 2013
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma